B
Bull
Bull · 25%SONN
$21.92
Precio del escenario
$1.260
-0.748 (-59.35%)Al cierre
Loading chart…
- High
- 3.230
- Open
- 3.160
- VWAP
- 1.92
- Vol
- 10.46M
- Mkt Cap
- 2.95M
- Low
- 1.260
- Amount
- 20.04M
- EV/EBITDA, TTM
- 0.00
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Métricas de valoración
The current forward P/E ratio for Sonnet Biotherapeutics Holdings Inc (SONN) is -0.36, compared to its 5-year average forward P/E of -0.65.
Alphio AI Price Scenarios for SONN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
8.512-02NewsfilterHyperliquid Completes Merger with Sonnet, Stock to Trade on Nasdaq
- 8.512-02Newsfilter
Sonnet BioTherapeutics Shareholders Approve Merger with Hyperliquid Strategies Inc.
8.512-02GlobenewswireSonnet BioTherapeutics Secures Shareholder Approval for Merger with Hyperliquid Strategies
2.012-01NASDAQ.COMBiotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet
- 1.009-19Newsfilter
Sonnet to Showcase at the MedInvest Biotech & Pharma Conference
SONN FAQ — answered by Alphio AI
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.